Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
De Mattos-Arruda L, Vazquez M, Finotello F, Lepore R, Porta E, Hundal J, Amengual-Rigo P, Ng CKY, Valencia A, Carrillo J, Chan TA, Guallar V, McGranahan N, Blanco J, Griffith M. De Mattos-Arruda L, et al. Among authors: chan ta. Ann Oncol. 2020 Aug;31(8):978-990. doi: 10.1016/j.annonc.2020.05.008. Epub 2020 Jun 28. Ann Oncol. 2020. PMID: 32610166 Free PMC article.
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Palmeri M, et al. ESMO Open. 2022 Feb;7(1):100336. doi: 10.1016/j.esmoop.2021.100336. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953399 Free PMC article.
Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis.
Do MH, Shi W, Ji L, Ladewig E, Zhang X, Srivastava RM, Capistrano KJ, Edwards C, Malik I, Nixon BG, Stamatiades EG, Liu M, Li S, Li P, Chou C, Xu K, Hsu TW, Wang X, Chan TA, Leslie CS, Li MO. Do MH, et al. Among authors: chan ta. Immunity. 2023 Nov 14;56(11):2555-2569.e5. doi: 10.1016/j.immuni.2023.10.010. Immunity. 2023. PMID: 37967531
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, Abraham J, Budd GT, Moore H, Al-Hilli Z, Ko JS, Baar J, Chan TA, Alban T, Diaz-Montero CM, Montero AJ. Wilkerson AD, et al. Among authors: chan ta. Clin Cancer Res. 2024 Jan 5;30(1):82-93. doi: 10.1158/1078-0432.CCR-23-1349. Clin Cancer Res. 2024. PMID: 37882661 Free PMC article. Clinical Trial.
Immunosurveillance in clinical cancer management.
Kroemer G, Chan TA, Eggermont AMM, Galluzzi L. Kroemer G, et al. Among authors: chan ta. CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25. CA Cancer J Clin. 2024. PMID: 37880100 Free article. Review.
292 results